A5066251595- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Immune responses and vaccinations
- Aldose Reductase and Taurine
- Alcohol Consumption and Health Effects
- Ferroptosis and cancer prognosis
- HIV/AIDS drug development and treatment
- Drug-Induced Hepatotoxicity and Protection
- Folate and B Vitamins Research
- Vitamin D Research Studies
- Liver physiology and pathology
- Cancer, Hypoxia, and Metabolism
- Immunodeficiency and Autoimmune Disorders
- Cytokine Signaling Pathways and Interactions
- Mesenchymal stem cell research
- Cancer Genomics and Diagnostics
- Vitamin C and Antioxidants Research
- Pharmacological Effects and Toxicity Studies
- Immune cells in cancer
China Medical University
2016-2025
Sheng Jing Hospital
2012-2024
Xiangya Hospital Central South University
2024
Central South University
2024
Lanzhou University
2024
Lanzhou University Second Hospital
2024
Shandong University
2021-2023
Peking University People's Hospital
2016
Peking University
2016
Xiamen University
2015
Background & AimsWe performed a nationwide, retrospective study to determine the incidence and causes of drug-induced liver injury (DILI) in mainland China.MethodsWe collected data on total 25,927 confirmed DILI cases, hospitalized from 2012 through 2014 at 308 medical centers China. We demographic, history, treatment, laboratory, disease severity, mortality all patients. Investigators each site were asked complete causality assessments for case whose diagnosis discharge was (n = 29,478)...
•In total, 17,374 patients with viral and non-viral hepatitis from 11 global prospective cohorts/trials were studied.•An HCC risk score (called the aMAP score, ranging 0 to 100), which involves only age, male, albumin–bilirubin platelet data, was developed validated.•The had excellent discrimination calibration in assessing 5-year irrespective of aetiology ethnicity.•Patients <50, accounting for 44% overall population, an incidence <0.2% per year. Background & AimsHepatocellular carcinoma...
Background and Aims: Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a. We assessed HBsAg 48- 96-week Peg-IFN alfa-2a partial response a previous NA. Methods: e (HBeAg)-positive who HBeAg virus DNA <200 IU/mL adefovir, lamivudine or entecavir treatment were randomized 1:1 receive for 48 (n = 153) 96 weeks 150). The primary endpoint...
Chronic hepatitis C virus (HCV) infection is relatively frequent in China. This study investigated the clinical, demographic, and viral host genetic characteristics that may influence disease manifestations clinical management.In this cross-sectional observational study, treatment-naïve Han ethnic adults with recently confirmed chronic HCV were enrolled at 28 hospitals across genotype interleukin 28B (IL28B) genotypes determined compared patient demographic parameters medical status.Among...
There is no satisfactory way to identify patients who will maintain a response after discontinuation of nuleos(t)ide analogue therapy for chronic hepatitis B virus (HBV) infection. We investigated whether with negative results from tests HBV DNA and RNA (double negative) at the end treatment long-term treatment.We performed post-hoc analysis data 2-year multi-center randomized controlled trial, its extension trials, on 130 infection were positive HB e antigen (HBeAg-positive; mean age, 30.8...
Current hepatocellular carcinoma (HCC) risk scores do not reflect changes in HCC resulting from liver disease progression/regression over time. We aimed to develop and validate two novel prediction models using multivariate longitudinal data, with or without cell-free DNA (cfDNA) signatures.A total of 13,728 patients nationwide multicenter prospective observational cohorts, the majority whom had chronic hepatitis B, were enrolled. aMAP score, as one most promising models, was evaluated for...
Hepatitis B surface antigen (HBsAg) loss is the optimal outcome for patients with chronic hepatitis (CHB) but this rarely occurs currently approved therapies. We aimed to develop and validate a prognostic model HBsAg on treatment using longitudinal data from large, prospectively followed, nationwide cohort.
An optimization strategy based on the Roadmap concept is supposed to improve clinical outcomes of patients with suboptimal antiviral response. The aim this study was prove a multicenter, open-label, randomized, controlled study. In all, 606 hepatitis B e antigen (HBeAg)-positive, nucleos(t)ide-naive chronic were randomized Optimize or Mono group. Patients in group treated telbivudine for 24 weeks, after which those responders HBV DNA ≥300 copies/mL at week received plus adefovir until 104,...
The main transmission route of the hepatitis B virus (HBV) is mother to child and contributes significantly chronic HBV infection. Even though immunoprophylaxis with immunoglobulin (HBIG) vaccine administrated neonates whose mothers are surface antigen (HBsAg) positive, about 10% suffer from infection in their early life.To survey among pregnant women infants analyze reason for failure.Serum HBsAg was tested all women. HBVDNA other serum markers including e (HBeAg), core antibody (anti-HBc)...
Summary Liver biopsy is not routinely performed in treated chronic hepatitis B. stiffness measurement has been validated for noninvasive liver fibrosis assessment pretreatment B but assessed monitoring during antiviral therapy. was systemically monitored by Fibroscan ® every 6 months a cohort of patients with receiving therapy and compared biopsies at baseline week 104. A total 534 e antigen‐positive treatment‐naive telbivudine‐based qualified 104 were analyzed, 164 which had adequate paired...
Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries. We evaluated sofosbuvir/ledipasvir 12 weeks a 48-week pegIFN-RBV regimen Chinese patients genotype 1b HCV infection by economic regions.A decision analytic Markov model was developed to estimate quality-adjusted-life-years, lifetime cost incremental ratios (ICERs). SVR rates direct medical...
Chronic pancreatitis is characterized by progressive fibrosis, pain and loss of exocrine endocrine functions. The long-standing chronic its associated pancreatic fibrosis are the most common pathogenic events involved in human carcinogenesis, but therapeutic strategies to chemoprevention carcinogenesis very limited.We investigated effect sulindac, a non-steroidal anti-inflammatory drug (NSAID), on inhibition caerulein induced mouse model.Sulindac significantly reduced severity including...
Preventing hepatitis B virus (HBV) mother-to-child transmission (MTCT) is the key to controlling prevalence of chronic HBV infection. Adequate awareness in s antigen (HBsAg) positive pregnant women may be helpful reduce MTCT. The aim this study was explore seroprevalence among and investigate level HBsAg women. serum biomarkers were tested visiting Shengjing Hospital China Medical University. HBsAg-positive received a DNA test completed questionnaire. different loads interpreted as follows:...
Undifferentiated embryonal sarcoma of the liver (UESL) is a rare malignancy originating from primary mesenchymal tissue. The clinical manifestations, laboratory tests, and imaging examinations disease lack specificity preoperative misdiagnosis rate high. overall prognosis poor survival low.To investigate diagnosis, treatment, UESL.We performed retrospective, single-center cohort study in Shengjing Hospital China Medical University, which central hospital northeast China. From 2005 to 2017,...
Summary Background Obesity is typically associated with metabolic dysfunction, but its impact on hepatocellular carcinoma (HCC) remains unclear in patients chronic hepatitis B (CHB). Aim To study the effect of obesity HCC development CHB receiving antiviral therapy. Methods We included from a Chinese multicentre, prospective, observational, treated cohort this study. General was evaluated by body‐mass index (BMI). Central waist circumference, waist‐to‐hip ratio and waist‐to‐height ratio....
The World Health Organization (WHO) has set the goal of eliminating hepatitis as a threat to public health by 2030. Blocking mother-to-child transmission (MTCT) B virus (HBV) is not only key viral hepatitis, but also hot issue in field prevention and treatment. To standardize clinical management preventing MTCT HBV achieve zero infection among infants, Chinese Foundation for Hepatitis Prevention Control organized experts compile algorithm based on latest research progress guidelines,...